ArticleChinese medical journal2024
Socioeconomic inequalities in cancer incidence and mortality: An analysis of GLOBOCAN 2022.
Article in Chinese medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Updated evaluation of additional surgery versus non-gastrectomy treatment for early gastric cancer after noncurative endoscopic resection: a meta-analysis.Surgical endoscopy · 2026Pooled it
- Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis.Chinese medical journal · 2026Pooled it
- Lifetime risk of respiratory system cancers across 185 countries: Global variation, socioeconomic inequalities, and ecological associations with air pollution.Preventive medicine reports · 2026Article
- A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management.Journal of thoracic disease · 2026Review
- Conversion surgery after immunotherapy and chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology: A retrospective cohort study.Chinese medical journal · 2026Article
- A cigarette compound-induced tumor microenvironment promotes sorafenib resistance in hepatocellular carcinoma via the 14-3-3η-modified tumor-associated proteome.Chinese medical journal · 2026Article
- Chrononutrition variables and thyroid function: evidence for a specific role of the time of the first meal.European journal of nutrition · 2026Article
- Proteomic analysis reveals modulation of key proteins in follicular thyroid cancer progression.Chinese medical journal · 2026Article
- Global inequalities in tracheal, bronchus, and lung cancer care quality from 1990 to 2021.iScience · 2026Article
- A bibliometric analysis of post-translational modifications in esophageal cancer based on the Web of Science Core Collection database [2000-2026].Journal of thoracic disease · 2026Article
- Burden and Trends of Genitourinary Cancers Across the Americas: A GBD 2023 Analysis of Regional Socioeconomic Gradients.Cancers · 2026Article
- An investigative network analysis mapping global cancer epidemiology.Theory in biosciences = Theorie in den Biowissenschaften · 2026Article
- Individual and combined effects of marital status, household income, and residence on cancer management and survival in primary bone cancer: a SEER-based retrospective cohort study.Translational cancer research · 2026Article
- Comparison of survival outcomes between kidney transplant and dialysis in patients with previous cancer.Chinese medical journal · 2026Observational
- Comparison of breast cancer awareness and attitudes toward screenings in women with and without a family history.BMC cancer · 2026Article
- Regional and national burden of six major digestive cancers in Asia, 1990-2023: An analysis of the GBD Study 2023.iScience · 2026Article
- Click chemistry of phenyl 1,2,3-triazole-2-pyridylpiperazine hybrids: synthesis, targeted anticancer activity, molecular modeling and computational studies.RSC advances · 2026Article
- Early Birds and Thyroid Cancer: Unveiling the Link Between Morningness and Thyroid Cancer Risk Through Mendelian Randomization.Brain and behavior · 2026Article
- Greater Attention to Gingival Cancer and Floor of Mouth Cancer: Based on a Retrospective Analysis of Oral Cancer Across Different Subsites.Head & neck · 2026Article
- Development of a self-management manual for patients with refractory cancer pain treated with a semi-implantable intrathecal drug delivery system: a Delphi study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the recent updates in cancer burden estimates by GLOBOCAN 2022, this study was undertaken to provide pertinent perspectives within the context of the Human Development Index (HDI) and major world economies.
methodsDatasets sourced from GLOBOCAN encompassed cancer cases and deaths across all cancer types in 2022, alongside projections up to 2050. Cancer incidences and deaths of the top 10 cancers within China and four distinct HDI-classified regions were compared using descriptive analyses. Age-standardized incidence rates (ASIRs) and mortality rates (ASMRs) worldwide for the most prevalent cancers in 2022 across ten largest economies and four-tier HDIs were examined. The top five cancer types concerning both incidence and mortality in China were delineated by sex and age group.
resultsIn males, prostate cancer predominated in countries with low, high (except China), and very high HDI. Prostate and liver cancers were prominent causes of death in countries with low HDI. In females, breast and cervical cancers predominated in countries with low-to-medium HDI. Lung and colorectal cancer incidence and deaths increased with high HDI for both sexes. ASIRs and ASMRs for breast, prostate, lung, and colorectal cancers in the top 10 economies were higher than the global average. However, liver, stomach, and cervical cancers in most Western countries exhibited lower rates. In China, hematologic malignancies (43%) were prevalent among children aged 0-14 years, whereas thyroid cancer led among adolescents and young adults aged 15-39 years. Regarding incidence and mortality, lung cancer predominated for individuals over 40 years, except for females aged 40-59 years, in whom breast cancer predominated. Projected trends indicated substantial increases in new cancer cases (76.6%) and deaths (89.7%) over the next three decades.
conclusionsInfection- and poverty-related cancer burdens are offset by increased prostate, breast, colorectal, and lung cancer incidence associated with rapid societal and economic transitions. Cancer incidence and mortality patterns in China feature characteristics of developed and developing countries, necessitating tailored, evidence-based, and comprehensive strategies for effective cancer prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.